JAGSNPHARM Stock Overview
Engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Jagsonpal Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹464.25 |
| 52 Week High | ₹495.60 |
| 52 Week Low | ₹273.60 |
| Beta | 1.14 |
| 11 Month Change | 13.19% |
| 3 Month Change | 35.33% |
| 1 Year Change | 10.35% |
| 33 Year Change | 192.63% |
| 5 Year Change | 1,753.29% |
| Change since IPO | -31.02% |
Recent News & Updates
Recent updates
Some Confidence Is Lacking In Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) P/E
Oct 14
There May Be Some Bright Spots In Jagsonpal Pharmaceuticals' (NSE:JAGSNPHARM) Earnings
May 27There's Reason For Concern Over Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Massive 27% Price Jump
Apr 30A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Apr 05Investor Optimism Abounds Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) But Growth Is Lacking
Feb 06Estimating The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jul 29A Look At The Intrinsic Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
May 13Does Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Deserve A Spot On Your Watchlist?
Jul 05A Look At The Fair Value Of Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM)
Jun 13Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) 0.6% Dividend Yield Looks Pretty Interesting
Apr 19Should You Be Adding Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) To Your Watchlist Today?
Mar 21Jagsonpal Pharmaceuticals Limited's (NSE:JAGSNPHARM) Stock Is Going Strong: Have Financials A Role To Play?
Feb 08The Attractive Combination That Could Earn Jagsonpal Pharmaceuticals Limited (NSE:JAGSNPHARM) A Place In Your Dividend Portfolio
Jan 08Here's Why I Think Jagsonpal Pharmaceuticals (NSE:JAGSNPHARM) Is An Interesting Stock
Dec 21Are Jagsonpal Pharmaceuticals's (NSE:JAGSNPHARM) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Nov 30Shareholder Returns
| JAGSNPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -1.1% | -0.8% | -0.9% |
| 1Y | 10.4% | 60.3% | 39.7% |
Return vs Industry: JAGSNPHARM underperformed the Indian Pharmaceuticals industry which returned 60.3% over the past year.
Return vs Market: JAGSNPHARM underperformed the Indian Market which returned 39.7% over the past year.
Price Volatility
| JAGSNPHARM volatility | |
|---|---|
| JAGSNPHARM Average Weekly Movement | 7.4% |
| Pharmaceuticals Industry Average Movement | 6.1% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.4% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: JAGSNPHARM has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: JAGSNPHARM's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1978 | 1,025 | Manish Gupta | www.jagsonpal.com |
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups.
Jagsonpal Pharmaceuticals Limited Fundamentals Summary
| JAGSNPHARM fundamental statistics | |
|---|---|
| Market cap | ₹12.30b |
| Earnings (TTM) | ₹203.13m |
| Revenue (TTM) | ₹2.10b |
60.5x
P/E Ratio5.9x
P/S RatioIs JAGSNPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JAGSNPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹2.10b |
| Cost of Revenue | ₹801.84m |
| Gross Profit | ₹1.30b |
| Other Expenses | ₹1.09b |
| Earnings | ₹203.13m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 23, 2024
| Earnings per share (EPS) | 7.67 |
| Gross Margin | 61.82% |
| Net Profit Margin | 9.67% |
| Debt/Equity Ratio | 4.8% |
How did JAGSNPHARM perform over the long term?
See historical performance and comparison